Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated MyelofibrosisJean‐Jacques Kiladjian, Bruno Cassinat, Françoise Boyer‐Perrard et al.|Blood|2018Cited by 26
A molecular signature predicts hematologic evolution in polycythemia vera patientsOlivier Mansier, Éric Lippert, Lina Benajiba et al.|Leukemia|2025Cited by 1